A Simulation Study of the Effect of Clinical Characteristics and Treatment Choice on Reliever Medication Use, Symptom Control and Exacerbation Risk in Moderate–Severe Asthma
Open Access
- 25 June 2024
- journal article
- research article
- Published by Springer Nature in Advances in Therapy
- Vol. 41 (8) , 3196-3216
Abstract
Introduction The relationship between immediate symptom control, reliever medication use and exacerbation risk on treatment response and factors that modify it have not been assessed in an integrated manner. Here we apply simulation scenarios to evaluate the effect of individual baseline characteristics on treatment response in patients with moderate–severe asthma on regular maintenance dosing monotherapy with fluticasone propionate (FP) or combination therapy with fluticasone propionate/salmeterol (FP/SAL) or budesonide/formoterol (BUD/FOR). Methods Reduction in reliever medication use (puffs/24 h), change in symptom control scores (ACQ-5), and annualised exacerbation rate over 12 months were simulated in a cohort of patients with different baseline characteristics (e.g. time since diagnosis, asthma control questionnaire (ACQ-5) symptom score, smoking status, body mass index (BMI) and sex) using drug–disease models derived from large phase III/IV clinical studies. Results Simulation scenarios show that being a smoker, having higher baseline ACQ-5 and BMI, and long asthma history is associated with increased reliever medication use (p < 0.01). This increase correlates with a higher exacerbation risk and higher ACQ-5 scores over the course of treatment, irrespective of the underlying maintenance therapy. Switching non-responders to ICS monotherapy to combination therapy after 3 months resulted in immediate reduction in reliever medication use (i.e. 1.3 vs. 1.0 puffs/24 h for FP/SAL and BUD/FOR, respectively). In addition, switching patients with ACQ-5 > 1.5 at baseline to FP/SAL resulted in 34% less exacerbations than those receiving regular dosing BUD/FOR (p < 0.01). Conclusions We have identified baseline characteristics of patients with moderate to severe asthma that are associated with greater reliever medication use, poor symptom control and higher exacerbation risk. Moreover, the effects of different inhaled corticosteroid (ICS)/long-acting beta agonist (LABA) combinations vary significantly when considering long-term treatment performance. These factors should be considered in clinical practice as a basis for personalised management of patients with moderate–severe asthma symptoms.Keywords
Funding Information
- GlaxoSmithKline
This publication has 62 references indexed in Scilit:
- In Silico Clinical Trials: Is It Possible?2023
- Understanding the Clinical Implications of Individual Patient Characteristics and Treatment Choice on the Risk of Exacerbation in Asthma Patients with Moderate–Severe SymptomsAdvances in Therapy, 2023
- Moving Toward a Question‐Centric Approach for Regulatory Decision Making in the Context of Drug AssessmentClinical Pharmacology & Therapeutics, 2023
- Role of Disease Progression Models in Drug DevelopmentPharmaceutical Research, 2022
- New Versus Old: The Impact of Changing Patterns of Inhaled Corticosteroid Prescribing and Dosing Regimens in Asthma ManagementAdvances in Therapy, 2022
- Pharmacology Versus Convenience: A Benefit/Risk Analysis of Regular Maintenance Versus Infrequent or As-Needed Inhaled Corticosteroid Use in Mild AsthmaAdvances in Therapy, 2021
- Stability of sputum inflammatory phenotypes in childhood asthma during stable and exacerbation phasesPediatric Pulmonology, 2021
- Asthma epidemiology and risk factorsSeminars in Immunopathology, 2020
- MID3: Mission Impossible or Model‐Informed Drug Discovery and Development? Point‐Counterpoint Discussions on Key ChallengesClinical Pharmacology & Therapeutics, 2020
- PKPD and Disease Modeling: Concepts and Applications to Oncology2010